Irbesartán/Hidroclorotiazida Almus (Hydrochlorothiazide, Irbesartan)

Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing the hormone from causing vasoconstriction and stimulating aldosterone release. This results in relaxed blood vessels, reduced sodium and water retention, and ultimately lower arterial pressure.

The specific dose is determined by the prescribing clinician based on the patient’s blood pressure, renal function, and other medications. The product is supplied as oral tablets in defined strengths, and the prescriber selects the appropriate strength and dosing schedule.

Use during pregnancy, especially in the second and third trimesters, is generally contraindicated because of potential fetal harm. Safety during breastfeeding has not been established, so the medication should be avoided unless the benefit to the mother clearly outweighs the potential risk to the infant.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy, the irbesartan/hydrochlorothiazide combo offers dual mechanisms—vascular relaxation and diuresis—allowing better blood‑pressure control in patients who need more than one agent, while reducing pill burden versus taking separate tablets of each component.

The tablets should be stored at ambient temperature, below 25 °C, in the original packaging, protected from moisture, light and excessive heat. Proper storage helps maintain the product’s potency throughout its shelf‑life.

The medication is taken orally, usually once daily in the morning, with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water; it is not intended for crushing or chewing.

Patients should be alert for severe allergic reactions such as facial or throat swelling, marked drops in blood pressure, significant electrolyte disturbances like hyperkalemia, and signs of kidney impairment. Any of these symptoms require immediate medical evaluation.

Individuals with known hypersensitivity to irbesartan, hydrochlorothiazide or any excipients, those with severe renal or hepatic impairment, and pregnant women in the second or third trimester should avoid this product unless a physician determines it is essential.